A metabolic inhibitor blocks cellular fucosylation and enables production of afucosylated antibodies.
Pierre-André GilorminiV Narasimharao ThotaAnthony Fers-LidouRoger A AshmusMatthew NodwellJacob BrockermanChu-Wei KuoYang WangTaylor E Gray NitinAnthony W McDonaghShih-Yun GuuNurşah Ertunç HasbalDominick YeoWesley F ZandbergKai-Hooi KhooRobert A BrittonDavid J VocadloPublished in: Proceedings of the National Academy of Sciences of the United States of America (2024)
The fucosylation of glycoproteins regulates diverse physiological processes. Inhibitors that can control cellular levels of protein fucosylation have consequently emerged as being of high interest. One area where inhibitors of fucosylation have gained significant attention is in the production of afucosylated antibodies, which exhibit superior antibody-dependent cell cytotoxicity as compared to their fucosylated counterparts. Here, we describe β-carbafucose, a fucose derivative in which the endocyclic ring oxygen is replaced by a methylene group, and show that it acts as a potent metabolic inhibitor within cells to antagonize protein fucosylation. β-carbafucose is assimilated by the fucose salvage pathway to form GDP-carbafucose which, due to its being unable to form the oxocarbenium ion-like transition states used by fucosyltransferases, is an incompetent substrate for these enzymes. β-carbafucose treatment of a CHO cell line used for high-level production of the therapeutic antibody Herceptin leads to dose-dependent reductions in core fucosylation without affecting cell growth or antibody production. Mass spectrometry analyses of the intact antibody and N -glycans show that β-carbafucose is not incorporated into the antibody N -glycans at detectable levels. We expect that β-carbafucose will serve as a useful research tool for the community and may find immediate application for the rapid production of afucosylated antibodies for therapeutic purposes.